| Drug-Induced Adverse Reactions | Lifetime | 1 | GB 1 | 99.83 |
| Pharmaceutical studies and practices | Lifetime | 7 | GB 1 | 99.82 |
| Pharmacogenetics and Drug Metabolism | Lifetime | 9 | GB 1 | 99.81 |
| Pharmacovigilance and Adverse Drug Reactions | Lifetime | 2 | GB 1 | 99.81 |
| Drug-Induced Hepatotoxicity and Protection | Lifetime | 16 | GB 1 | 99.76 |
| Pharmaceutical Practices and Patient Outcomes | Lifetime | 51 | GB 5 | 99.15 |
| Biosimilars and Bioanalytical Methods | Lifetime | 31 | GB 3 | 98.94 |
| Pharmacological Effects and Toxicity Studies | Lifetime | 133 | GB 12 | 99.12 |
| Drug Transport and Resistance Mechanisms | Lifetime | 186 | GB 13 | 99.02 |
| Health Systems, Economic Evaluations, Quality of Life | Lifetime | 532 | GB 85 | 98.69 |
| Computational Drug Discovery Methods | Lifetime | 385 | GB 25 | 98.18 |
| Pneumocystis jirovecii pneumonia detection and treatment | Lifetime | 279 | GB 24 | 98.41 |
| Urticaria and Related Conditions | Lifetime | 201 | GB 13 | 98.08 |
| Autoimmune Bullous Skin Diseases | Lifetime | 310 | GB 28 | 97.72 |
| Berberine and alkaloids research | Lifetime | 90 | GB 4 | 95.50 |
| Eicosanoids and Hypertension Pharmacology | Lifetime | 617 | GB 46 | 96.53 |
| HIV/AIDS drug development and treatment | Lifetime | 958 | GB 56 | 97.12 |
| Statistical Methods in Clinical Trials | Lifetime | 394 | GB 56 | 95.51 |
| Mast cells and histamine | Lifetime | 571 | GB 39 | 95.02 |
| HIV-related health complications and treatments | Lifetime | 699 | GB 41 | 95.11 |
| Blood disorders and treatments | Lifetime | 698 | GB 55 | 93.22 |
| Pharmaceutical Economics and Policy | Lifetime | 745 | GB 88 | 92.67 |
| Drug-Induced Ocular Toxicity | Lifetime | 657 | GB 52 | 71.96 |
| Pharmaceutical Quality and Counterfeiting | Lifetime | 671 | GB 70 | 55.64 |
| Pharmacogenetics and Drug Metabolism | 2021-2025 | 2 | GB 1 | 99.23 |
| Pharmaceutical studies and practices | 2021-2025 | 15 | GB 1 | 98.11 |
| Pharmaceutical Practices and Patient Outcomes | 2021-2025 | 55 | GB 7 | 97.25 |
| Pharmacovigilance and Adverse Drug Reactions | 2021-2025 | 13 | GB 1 | 97.34 |
| Computational Drug Discovery Methods | 2021-2025 | 402 | GB 11 | 95.23 |
| Health Systems, Economic Evaluations, Quality of Life | 2021-2025 | 721 | GB 94 | 94.40 |
| Drug-Induced Adverse Reactions | 2021-2025 | 115 | GB 8 | 91.99 |
| Genomics and Rare Diseases | 2021-2025 | 631 | GB 69 | 88.44 |
| Biosimilars and Bioanalytical Methods | 2021-2025 | 304 | GB 18 | 87.31 |
| Blood disorders and treatments | 2021-2025 | 159 | GB 9 | 87.01 |
| Alcohol Consumption and Health Effects | 2021-2025 | 762 | GB 45 | 79.06 |
| Biomedical Text Mining and Ontologies | 2021-2025 | 663 | GB 51 | 70.53 |
| Inflammatory mediators and NSAID effects | 2021-2025 | 579 | GB 22 | 66.93 |
